Cairn Therapeutics

Founded with a mission to help patients overcome cancer, Cairn Therapeutics focuses on transforming cancer treatment by exploiting differences in the microenvironments between cancer cells and healthy cells. The company's flagship product, CT-262, is a groundbreaking DNA binding agent designed to revolutionize chemotherapy by reducing debilitating side effects and improving efficacy. Cairn Therapeutics aims to address the limitations of current cancer therapies, offering hope to patients who have not benefited from existing treatments.

Cairn Therapeutics has garnered attention from notable investors and industry experts committed to advancing cancer treatment. The company has achieved significant milestones in preclinical trials, showcasing the potential of CT-262 to improve patient outcomes. By pioneering innovative approaches in oncology, Cairn Therapeutics is making a substantial impact on the future of cancer care, striving to enhance the quality of life for patients worldwide.